TissueGen® is committed to developing next-generation technologies for advanced drug delivery, nerve regeneration and tissue engineering. If you would like to join our team, we would like hear from you. Please contact info@tissuegen.com



TissueGen® is committed to developing next-generation technologies for advanced drug

delivery, nerve regeneration, and tissue engineering. 

If you would like to join our team, we would like hear from you. 
Please contact info@tissuegen.com


M. Scott Salka
Chief Executive Officer

Scott is a biotechnology entrepreneur with a passion for developing medicines for patients with few or no effective therapeutic options for their diseases. He became CEO of TissueGen in 2019. In addition to leading TissueGen as CEO, Scott also serves as Executive Chair for Novosteo.  Before TissueGen, Scott served eight different biotechnology companies as co-founder and or CEO. He received his M.B.A. from Carnegie Mellon University, his B.S. in Finance from San Diego State University, and served as a U.S. Army soldier in the 7th Special Forces Group.

Dr. Kevin D. Nelson
Founder and Chief Scientific Officer

After completing his Ph.D. in 1995 in the field of biomedical engineering at The University of Texas Southwestern Medical Center in Dallas, Kevin joined the faculty at The University of Texas at Arlington where he earned tenure in 2003 and resigned in 2005 to become a full-time Founder and Chief Scientific Officer of TissueGen, Inc. He is an inventor on numerous patents that comprise the foundation of TissueGen's technology in the areas of drug protection and delivery. He continues to keep close to the university and currently serves as the head of the bioengineering industrial advisory board. 



Kevin Cordell

Mr. Cordell currently serves as President, U.S. Extremities, for Wright Medical Technology, Inc.  He received his Bachelor’s Degree in Finance from the University of Oklahoma.

James Dukowitz
Ph.D (Chairman)

Dr. Dukowitz has more than 35 years of experience in high-tech industries, with particular strengths in the areas of strategic planning, business development, communications, international marketing, and technology commercialization. He earned his Bachelor’s Degree in Mathematics from the University of Iowa and his Ph.D. in Political Science with an emphasis on Science, Technology, and Public Policy from the Massachusetts Institute of Technology. 

Jonathan Gibson

Mr. Gibson is the Chief Executive Officer and General Partner at Socratic Fund Management L.P., the firm he founded in 1997.  He has extensive experience in the investment and energy industry. He graduated from Lehigh University.

Charles Munson

Mr. Munson is Manager and President of NCC Nano, LLC dba NovaCentrix, and three additional companies involved in oil and gas production or minerals. He has over 25 years of experience in energy markets and technologies including photovoltaics and oil exploration and recovery. Mr. Munson graduated from Brown University with a dual degree in Geophysics and Math. 

Dr. Kevin D. Nelson
Founder and CSO

Kevin Nelson,  Founder and CSO, also serves on the Board of Directors.

Richard W. Snyder II

Dr. Snyder is a cardiologist at Medical City Dallas Hospital and board-certified in Cardiovascular Disease, Interventional Cardiology, Advanced Heart Failure, and Transplant Cardiology. After graduating from the University of Notre Dame, he completed medical school at the University of Texas Southwestern Medical School, with a residency in internal medicine and fellowship in cardiovascular disease.

Scott Salka
Chief Executive Officer

Scott Salka, CEO, also serves on the Board of Directors.



Andreas M. Sauerbrey

Dr. Sauerbrey is a board-certified, fellowship-trained orthopaedic surgeon specializing in shoulder/upper extremity surgery, sports medicine and joint restoration. He completed his medical degree in 1992 from Oregon Health Sciences University and orthopedic residency at the University of Colorado. He also completed a fellowship training in shoulder and elbow surgery at the University of Pennsylvania and a fellowship in hand surgery at Thomas Jefferson University in Philadelphia. He has been a team physician for the USSA (United States Ski and Snowboard Assoc.) and the US Ski Team since 2001.

Lisa A. Fortier

Dr. Fortier is a Professor of Surgery at Cornell University in Ithaca, NY.  She received her DVM from Colorado State University and completed her Ph.D. and surgical residency training at Cornell University.  Her expertise is in Equine orthopedic surgery and research and her current laboratory projects include equine embryonic stem cells, the role of Rho-subfamily GTPases in cartilage homeostasis, tetracyclines as therapeutics for arthritis, platelet rich plasma for tendon and suspensory ligament regeneration.

Richard W. Snyder II

Dr. Snyder serves on both the Board of Directors and the Medical Advisory Board at TissueGen.



Dr. Brent Crow
Director, Special Programs

Brent B. Crow, Ph.D., joined TissueGen in 2006 as Senior Project Scientist and assumed the role of Head, Special Programs in 2016. Prior to TissueGen, Brent served as chair of the Biomedical Engineering Technology department at DeVry University and worked at Lockheed Martin. 

Dr. Jennifer Seifert
Director, Research and Development

Jennifer Seifert, Ph.D., joined TissueGen in 2015 as Senior Scientist and assumed the role of Director, Research and Development in 2016. Prior to joining TissueGen, Jennifer held the position of Research Assistant Professor in the Department of Bioengineering at the University of Texas at Dallas. 

Dr. Ric Zarzycki
Director, Quality and Regulatory Affairs

Ric Zarzycki, PhD, joined TissueGen in 2018 as Director, Quality and Regulatory Affairs to lead the Company’s ISO 13485:2016 certification and provide regulatory support as the Company advances commercial applications for ELUTE fiber and related technologies. Dr. Zarzycki served for 21 years in numerous pharmaceutical and medical device Quality, Regulatory Affairs, and R&D at the University of Sheffield, before continuing postdoctoral work in Supramolecular Chemistry at Columbia University and his follow-on appointment as Assistant Professor in the Chemistry Department at the The University of Texas at Dallas.

Nickolas Griffin
MS, Production Manager

Nickolas Griffin joined TissueGen in 2009 and has served as the company’s Production Manager since 2011. Nickolas earned his Bachelor of Science in Biomedical Engineering from Texas A&M and is a proud member of the Fighting Texas Aggie class of 2007.


ISO Class 7 Clean Room

TissueGen develops ELUTE fiber in an ISO Class 7 cleanroom environment to support compliance with drug and medical device cGMP regulations.

ISO Certification

As an ISO 13485:2016 certified facility, we adhere to quality management system requirements for medical devices. Our processes and controls are designed to ensure quality, safety and reliability.

TissueGen, Inc.
2110 Research Row, Suite 330
Dallas, Texas 75235
+ 1.214.351.1922

  • Facebook
  • Twitter
  • Instagram

Site produced by Lovage Inc.